Dark Pulse Inc (DPLS) Stock Has Lost 60% From Recent High: A Good Buy Now?
Microcap stocks might be quite volatile but at the same time, investors need to keep in mind that these stocks can also deliver enormous gains within a short period of time. Hence, these stocks often attract plenty of followers.
One of the micro-cap stocks to have gained in popularity in recent weeks is that of Dark Pulse Inc (OTCMKTS:DPLS). Last month the stock had made a big jump but at this point, it is down by as much as 60% from its latest highs. In this sort of situation, it is important for investors to perhaps figure out if the fall in the stock could be an opportunity to get into it.
One of the most important things to point out with regards to the Dark Pulse stock is that it continues to be hugely popular from among micro-cap stocks and that had initially been the reason behind its remarkable rally. More importantly, some of the biggest players in penny stocks have taken note of the stock and that was another factor behind the strong rally.
On the other hand, the Dark Pulse stock is one of the most searched stocks among micro-cap stocks at this point in time and there is a fair degree of online buzz around it. Online chatter around a stock is a major factor that is hard to ignore. Hence, despite the fall from its high the Dark Pulse stock could be one to keep an eye on over the coming days.
Infinity Pharmaceuticals (NASDAQ:INFI) Stock Bounces Back After Yesterday’s Fall
On Tuesday, the Infinity Pharmaceuticals (NASDAQ:INFI) stock had suffered from a heavy selloff and had gone down by as much as 61%. However, this morning it is a different stock for the company as the stock has recovered strongly and gone up by as much as 38%.
There has been no fresh news about the company this morning and hence, the rally in the stock could be related to the announcement made by the company yesterday. On Tuesday, Infinity provided updates with regards to the MARIO-275 randomized placebo-based Phase 2 study into its flagship product eganelisib. In this study, the product, which is meant for reversing the immune suppression in cancer patients and spark anti-tumor activity, was administered to the patients in combination with nivolumab.
As per the data from the company that was released on Tuesday, the median overall survival figure when administered with this combination shot up to as much as 15.9 months. In comparison, patients who had only been administered with nivolumab had a median survival rate of 7.9 months. Hence, it is clear to see why the latest data released by Infinity Pharmaceuticals may have come as a source of considerable excitement for many investors.
The data suggests that if eganelisib is added to the standard medication for cancer patients, then there is a high chance of progression-free survival for patients. Hence, it is now going to be interesting to see if the stock can continue to add to its gains today in light of the positive data.